Infertility Drugs Market - Size, Share, Outlook, and
Opportunity Analysis, 2019 – 2026
Infertility is a global health issue as its affects both men and women. Infertility in females
occur due to increasing age, polycystic ovarian syndrome (PCOS), obesity, and multiple
miscarriages whereas in males infertility occur due to erectile dysfunction, low sperm count,
abnormal sperms, etc. Increasing prevalence of infertility is expected to propel demand for the
infertility drugs. According to World Health Organization (WHO) 2012 report, infertility affects
one out of four couples in emerging economies. Many researchers are working towards finding
an efficient treatment for the infertility. For instance, in 2018 at Ben-Gurion University (BGU),
Israel researchers were developing a new, single-dose infertility treatment based on a new
compound. The new treatment, developed by the BGU researchers, stimulates the expression of
the telomerase and re-elongates the telomeres, protecting the cells from damage.
Request Sample Copy of Research Report @ http://bit.ly/2W4lxIW
The global infertility drugs market size was valued at US$ 3.8 billion in 2017, and is expected
to witness a CAGR of 5.8% over the forecast period (2019 – 2026).
Increasing Research & Development for More Effective Treatment with Lesser Side-Effects to
Reduce Infertility is expected to Drive Growth of the Infertility Drugs Market
The infertility drugs market size is expected to witness significant growth, owing to the rising
research and developmental studies for more effective treatment to achieve pregnancy and live
births. For instance, in 2014, a team of researchers at National Institutes of Health’s (NIH)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
found that women treated with Letrozole have high rates of ovulation and live births than
women treated with the standard drug, Clomiphene. Furthermore, among women who received
Letrozole, 27.5% of them eventually had a live birth and women who received clomiphene,
only 19.1% them experienced a live birth. The cumulative ovulation rate was higher for the
Letrozole group, with ovulation occurring 61.7% of the time, and the women in the clomiphene
group ovulated 48.3% of the time.